Inventor · disambiguated record
William Querbes
Also filed as: QUERBES WILLIAM
36 granted patents·19 pending applications·253 citations·filing 2009–2025
98Inventor score
Files withALNYLAM PHARMACEUTICALS INC47FLAGSHIP PIONEERING INNOVATIONS VI LLC4AKING AKIN1ALNYIAM PHARMACEUTICALS INC1KAELIN JR WILLIAM G1
Top patents by PatentIndex Score
55 records- 0199US11525138B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Dec 13, 2022·7 cites·28 claims
- 0299US11130953B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Sep 28, 2021·8 cites·30 claims
- 0398US11866709B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 9, 2024·3 cites·29 claims
- 0498US11840692B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 12, 2023·3 cites·29 claims
- 0598US11834662B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 5, 2023·3 cites·29 claims
- 0698US11332743B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted May 17, 2022·6 cites·26 claims
- 0798US11306315B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
- 0898US11306314B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
- 0998US11306316B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
- 1098US9771591B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Sep 26, 2017·22 cites·34 claims
- 1198US9322018B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Apr 26, 2016·36 cites·41 claims
- 1297US11034958B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 15, 2021·7 cites·17 claims
- 1397US10557139B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Feb 11, 2020·15 cites·20 claims
- 1497US10550390B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Feb 4, 2020·15 cites·20 claims
- 1597US10337010B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Jul 2, 2019·17 cites·31 claims
- 1696US10934545B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 2, 2021·6 cites·25 claims
- 1795US10570393B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Feb 25, 2020·17 cites·46 claims
- 1895US9133461B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Sep 15, 2015·19 cites·58 claims
- 1992US12467051B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Nov 11, 2025·0 cites·13 claims
- 2092US12270029B2CFTR-modulating compositions and methodsFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2023·Granted Apr 8, 2025·3 cites·15 claims
- 2190US11198872B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Dec 14, 2021·6 cites·33 claims
- 2290US9631193B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Apr 25, 2017·8 cites·45 claims
- 2389US11408001B1Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 9, 2022·1 cites·29 claims
- 2489US11142766B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 12, 2021·4 cites·21 claims
- 2589US10407679B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·5 cites·43 claims
- 2688US2025034566A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2788US2025051765A1APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2887US12492401B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Dec 9, 2025·0 cites·23 claims
- 2987US10400239B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Sep 3, 2019·3 cites·51 claims
- 3087US10125369B2PCSK9 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Nov 13, 2018·9 cites·85 claims
- 3187US2024254486A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3286US11028392B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 8, 2021·1 cites·37 claims
- 3385US10478500B2Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Nov 19, 2019·4 cites·19 claims
- 3484US10125364B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Nov 13, 2018·2 cites·36 claims
- 3584US2025122505A1Compositions and methods for inhibiting expression of the alas1 geneALNYIAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3683US2025064936A1Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3782US2023068339A1APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3881US10119143B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Nov 6, 2018·3 cites·78 claims
- 3978US2020181614A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4077US9193973B2Compositions and methods for increasing erythropoietin (EPO) productionKAELIN JR WILLIAM G·Filed 2011·Granted Nov 24, 2015·2 cites·27 claims
- 4177US2023121944A1Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4277US2022403382A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4375US11446380B2Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Sep 20, 2022·0 cites·16 claims
- 4474US12460206B2PCSK9 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Nov 4, 2025·0 cites·2 claims
- 4574US2021087558A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4674US2023026968A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4773US2022119815A1Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4870US2020080088A1APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4969US2019218549A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 5067US2024252682A1Hbb-modulating compositions and methodsFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2024·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when William Querbes files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →